在人类动脉样硬化中,超氧化物生成和nox家族蛋白的表达
Dan Sorescu1, Daiana Weiss, Bernard Lassègue
1Department of Medicine, Emory University, Atlanta, Ga 30322, USA.
Circulation
|March 27, 2002
概括
包括gp91phox和Nox4在内的NAD(P) H氧化酶,有助于动脉样硬化中的氧化应激. 这些蛋白质定位在人类冠状动脉内的特定细胞中,影响疾病的进展.
科学领域:
- 心血管生物学 心血管生物学
- 氧化压力研究研究 氧化压力研究
- 动脉样硬化病原体的产生
背景情况:
- 在血管系统中,NAD(P) H氧化酶产生超氧化物.
- 与动脉样硬化风险因素相关的酶活性.
研究的目的:
- 调查超氧化物生产局部化情况.
- 在人类冠状动脉中确定诺克斯家族蛋白质表达 (gp91phox,Nox1,Nox4).
- 比较非动脉样硬化与动脉样硬化动脉中的表达.
主要方法:
- 在人类冠状动脉段中使用二乙检查了细胞内超氧化物生产.
- 评估了nox蛋白的表达和局部化 (gp91phox,nox1,nox4) 和p22phox.
- 与动脉样硬化严重程度和细胞含量相关的蛋白质表达 (巨细胞,α-actin阳性细胞).
主要成果:
- 在非动脉样硬化动脉中均地发现过氧化物.
- 在动脉样硬化动脉中,强烈的超氧化物局限于斑块肩部.
- gp91phox和p22phox主要在巨细胞中;Nox4在非细胞中;Nox1的表达很低.
- gp91phox/p22phox mRNA与动脉样硬化严重程度相关;gp91phox具有巨细胞含量;Nox4具有α-actin阳性细胞.
结论:
- gp91phox和Nox4在动脉样硬化中有助于氧化应激.
- 细胞特异性表达表明疾病起源和进展中的作用.
- 诺克斯蛋白与人类冠状动脉样硬化病有关.
相关概念视频
01:24Peroxisomes
13.6K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
13.6K
01:28Nitric Oxide Signaling Pathway
5.3K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741